

**Supplemental Table 1: ICD-9CM codes used in study methodology for diagnosis of PG, associated comorbidities, and exclusion of similar diagnoses, and procedure codes**

	<b>ICD-9 Codes</b>	<b>NIS Variables</b>
PG	686.01	DX1-DX25
IBD	555.xx, 556.xx	DX1-DX25
Acute myeloid leukemia	205.xx, 206.xx, 208.xx	DX1-DX25
Multiple myeloma	203.xx	DX1-DX25
Vasculitis and Henoch Schonlein Purpura	287.xx	DX1-DX25
Inflammatory Arthritis	714.xx	DX1-DX25
Monoclonal gammopathy of unknown significance	273.1	DX1-DX25
Strep carriage, chronic tonsillitis, and non-acute infections	034.0, 038.0, 463, 474.xx	DX1-DX25
Hypergammaglobulinemia	273.xx; 289.89	DX1-DX25
Intestinal blind loop syndrome	579.2	DX1-DX25
Sepsis	038.xx	DX1-DX25
Systemic inflammatory response syndrome	995.91, 995.92	DX1-DX25
Stoma complications	569.xx	DX1-DX25
Unspecified interstitial pneumonitis	495.9	DX1-DX25
Other specified alveolar and pareitoalveolar pneumonopathies cavitary pneumonia	516.8	DX1-DX25
Ocular complications	379.xx	DX1-DX25
Amputation stump complication	997.6x	DX1-DX25
Skin graft complication	996.52, 996.55	DX1-DX25
Flap/surgical wound complication	998.31	DX1-DX25
Skin graft	E878.2	ECODE1-ECODE4
	86.6x	PR1-PR15
Pedicle grafts/flap	86.7x	PR1-PR15
Amputation	E878.5	ECODE1-ECODE4
Skin biopsy	86.11	PR1-PR15
Stoma relocation/revision	E878.3	ECODE1-ECODE4
	46.4x	PR1-PR15
Hyperbaric oxygen	93.95	PR1-PR15
Debridement	86.22, 86.28	PR1-PR15
Intra-lesional injection	83.98	PR1-PR15
Granulomatosis with polyangiitis and related conditions / Polyarteritis nodosa and related conditions	446.xx	DX1-DX25
Sporotrichosis and deep cutaneous fungal infections	114.xx-117.xx	DX1-DX25
Anaplastic large cell lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphomas	200.6, 202.xx	DX1-DX25
Leukemia Curtis	709.8	DX1-DX25
Langerhans cell histiocytosis	202.xx	DX1-DX25
Anti-phospholipid antibody syndrome / Livedoid vasculopathy	289.81	DX1-DX25
Wound Infection	686.xx	DX1-DX25

Cellulitis	682.xx	DX1-DX25
Chronic Wound	707.xx	DX1-DX25

---

**Supplemental Table 2:** Demographics of 31 885 patient hospitalizations for pyoderma gangrenosum

	<b>PG Patients N = 31,885</b>	
<b>Age (mean, SE)</b>	55.31	0.31
<b>Gender</b>		
<b>Male</b>	10,474	32.87%
<b>Female</b>	21,386	67.13%
<b>Race</b>		
<b>White</b>	18,139	56.89%
<b>Black</b>	4,444	13.94%
<b>Hispanic</b>	1,721	5.40%
<b>Other</b>	7,580	23.77%
<b>Income quartile</b>		
<b>1</b>	7,824	25.03%
<b>2</b>	8,089	25.87%
<b>3</b>	7,791	24.92%
<b>4</b>	7,559	24.18%
<b>Type of insurance</b>		
<b>Medicare</b>	14,568	45.81%
<b>Medicaid</b>	4,005	12.59%
<b>Private</b>	10,361	32.58%
<b>Other</b>	2,867	9.02%
<b>Hospital type</b>		
<b>Rural</b>	3,058	9.65%
<b>Urban nonteaching</b>	12,059	38.06%
<b>Urban teaching</b>	16,566	52.29%
<b>Hospital size</b>		
<b>Small</b>	3,302	10.42%
<b>Medium</b>	6,761	21.34%
<b>Large</b>	21,619	68.24%
<b>Hospital region</b>		
<b>Northeast</b>	5,924	18.58%
<b>Midwest</b>	7,860	24.65%
<b>South</b>	12,563	39.40%
<b>West</b>	5,537	17.37%
<b>Elixhauser comorbidity score</b>		
<b>&lt;3</b>	16,886	66.43%
<b>≥3</b>	8,534	33.57%
<b>COMORBIDITIES (hierarchy)</b>		
<b>IBD</b>	8,453	26.51%
<b>Inflammatory Arthritis</b>	2,345	7.35%
<b>Vasculitis and Henoch Schonlein</b>	795	2.49%

<b>Purpura</b>		
<b>Hematologic malignancy and Dyscrasia</b>	886	2.78%
<b>Others</b>	19,405	60.86%

---

**COMPLICATIONS / ASSOCIATED DIAGNOSES AND OUTCOMES**

---

<b>Sepsis</b>	2,136	6.70%
<b>Systemic inflammatory response syndrome</b>	1,628	5.10%
<b>Stoma complications</b>	1,754	5.50%
<b>Post Surgical Complication</b>	267	0.84%
<b>Wound Infection</b>	31,885	100.00%
<b>Cellulitis</b>	8,598	26.96%
<b>Chronic Wound</b>	8,872	27.82%
<b>Mortality</b>	731	2.30%
<b>Length of Stay (mean, SE)</b>	8.15	0.14
<b>Cost (mean, SE)</b>	13,159	300

---

**PROCEDURES**

---

<b>Skin graft</b>	898	2.82%
<b>Skin biopsy</b>	3,834	12.02%
<b>Debridement</b>	3,518	11.03%
<b>None of the above</b>	24,913	78.14%

---

**SKIN BIOPSY PROCEDURE VOLUME**

---

<b>None</b>	1,509	4.73%
<b>Low (1-10 per year)</b>	11,783	36.95%
<b>High (&gt;10 per year)</b>	18,593	58.31%

---

**AHRQ ELIXHAUSER COMORBIDITIES**

---

<b>AIDS</b>	51	0.16%
<b>Alcohol abuse</b>	613	1.94%
<b>Anemia</b>	9,186	29.05%
<b>Rheumatoid arthritis / collagen vascular disease</b>	3,640	11.51%
<b>Chronic blood loss</b>	859	2.72%
<b>Congestive heart failure</b>	2,891	9.14%
<b>Chronic lung disease</b>	5,199	16.44%
<b>Coagulopathy</b>	1,495	4.73%
<b>Depression</b>	4,184	13.23%

<b>Diabetes mellitus</b>	5,806	18.36%
<b>Diabetes with chronic complications</b>	1,899	6.00%
<b>Drug abuse</b>	1,339	4.23%
<b>Hypertension</b>	13,652	43.16%
<b>Hypothyroidism</b>	3,271	10.34%
<b>Liver disease</b>	1,299	4.11%
<b>Lymphoma</b>	210	0.66%
<b>Fluid and electrolyte disorders</b>	7,869	24.88%
<b>Metastatic cancer</b>	297	0.94%
<b>Neurological disease</b>	1,501	4.75%
<b>Paralysis</b>	457	1.45%
<b>Obesity</b>	3,891	12.30%
<b>Peripheral vascular disease</b>	2,349	7.43%
<b>Psychoses</b>	1,246	3.94%
<b>Pulmonary circulation disorders</b>	483	1.53%
<b>Renal failure</b>	2,895	9.15%
<b>Solid tumor without metastasis</b>	427	1.35%
<b>Peptic ulcer disease</b>	78	0.25%
<b>Valvular disease</b>	1,291	4.08%
<b>Weight loss</b>	2,467	7.80%

---